As part of a worldwide effort to find better ways to treat the disease, Janssen joined the Global CEO Initiative on Alzheimer’s Disease (CEOi), a collaboration of public and private partnerships with shared goals of advancing prevention and effective treatment. The CEOi represents robust partnerships between public authorities, domestic and international, and the private sector to stop Alzheimer's disease and dementia. By working together and in partnership with leading non-governmental organizations and governments, this initiative will identify and pursue research, therapy development, financing and public awareness projects of the highest priority that, when achieved, can transform the global fight to stop Alzheimer’s disease.
Within the scope of the CEOi, Janssen and the Critical Path Institute's Coalition Against Major Diseases (CAMD) lead the Pipeline Compression group that is focusing on ways to reduce the time, cost and risk in developing therapies and treatments. To do this, the group looks at establishing common data standards to facilitate scientific collaborations and accelerate United States Food and Drug Administration (FDA) review of drug applications; achieving breakthroughs in developing and qualifying Alzheimer's disease biomarkers; developing robust patient registries to accelerate clinical trial recruitment; and expanding access to clinical trial data to prevent duplicative research, reduce unnecessary costs, risks and accelerate the pace of development of therapies and treatments.
To learn more, visit www.ceoalzheimersinitiative.org/.